Novavax has published the first clinical data for a combined Covid-19 and flu vaccine, with promising initial findings that a two-in-one shot could be safe and effective.
The trial, conducted in Australia, studied the combined shot in almost 650 people aged 50 to 70. An initial analysis found that their immune responses were similar to that for Novavax’s standalone Covid-19 vaccine and its flu vaccine candidate, which is waiting for regulatory approval. The safety profile was also similar to the individual vaccines, with no serious adverse events.
Novavax said that it expected to start a bigger phase 2 trial before the end of the year and the vaccine could be ready for rollout by the end of 2023.
您已阅读27%（706字），剩余73%（1910字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。